Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Humphrey J"'
Autor:
Joseph Omorogbe, Rana B. Haider, Niall Breslin, Sinead M. Smith, Grainne Holleran, Humphrey J. O'Connor, Denise Brennan, Barry Hall, Deirdre McNamara, Colm O'Morain
Publikováno v:
European Journal of Gastroenterology & Hepatology. 27:1265-1269
Eradication rates for the standard first-line triple therapy for Helicobacter pylori infection have decreased in recent years. Sequential therapy has been suggested as an alternative. The efficacy of sequential therapy has not been assessed to date i
Publikováno v:
European Journal of Gastroenterology & Hepatology. 26:819-825
Eradication rates of first-line triple therapy for Helicobacter pylori infection have fallen in the recent years. The main reasons for treatment failure are poor compliance due to complicated treatment regimens and the emergence of antibiotic-resista
Autor:
Colm O'Morain, Anthony O'Connor, Asghar Qasim, A Nami, Philip Murphy, Niall Breslin, Niamh Fitzgerald, Barbara Ryan, Ikue Taneike, Humphrey J. O'Connor
Publikováno v:
European Journal of Gastroenterology & Hepatology. 22:1123-1127
Introduction Helicobacter pylori eradication rates have fallen considerably in recent years. Antibiotic resistance is thought to be rising. Objectives To examine the levels of resistance to metronidazole (MTZ) and clarithromycin (CLA) in H. pylori, i
Autor:
Shaji Sebastian, Humphrey J. O'Connor, Ramona McLoughlin, Martin Buckley, Sharon McDonald, Colm O'Morain, Asghar Qasim
Publikováno v:
Scandinavian Journal of Gastroenterology. 42:194-199
6-Thioguanine has been used as an alternative immunomodulator in the treatment of inflammatory bowel disease but data on its efficacy and safety are limited. The aim of this study was to analyse our experience of the efficacy and safety of 6-thioguan
Autor:
Shaji Sebastian, Orla Thornton, Mark J. Dobson, Humphrey J. O'Connor, Colm O'Morain, Ramona McLoughlin, Martin Buckley, Asghar Qasim
Publikováno v:
Alimentary Pharmacology and Therapeutics. 21:91-96
SUMMARY Background: Optimal management approach is not well defined for subjects who fail initial first- and second-line Helicobacter pylori eradication attempts and are dealt on a case-by-case basis by the specialists. Aim: To evaluate the efficacy
Publikováno v:
Alimentary Pharmacology & Therapeutics. 12:273-276
Background: Seven-day proton pump inhibitor triple therapy is currently the treatment of choice for Helicobacter pylori infection. It is unclear whether triple therapy for less than 7 days might preserve efficacy while at the same time improving pati
Autor:
Barbara Ryan, Anthony O'Connor, Colm O'Morain, A Nami, Ikue Taneike, Deirdre McNamara, Niall Breslin, Philip Murphy, N. Fitzgerald, Humphrey J. O'Connor
Publikováno v:
Irish journal of medical science. 182(4)
Helicobacter pylori eradication rates using conventional triple therapies are falling, making viable second-line and rescue regimens necessary. Levofloxacin, tetracycline and rifabutin are three efficacious antibiotics for rescue therapy. We aimed to
Autor:
Barbara Ryan, Maria O'Sullivan, Sarah O'Donnell, Malik M Anwar, Niall Breslin, Colm O'Morain, Humphrey J. O'Connor, Stephen J.X. Murphy
Publikováno v:
European journal of gastroenterologyhepatology. 23(7)
Assessment of the long-term safety of anti-tumour necrosis factor therapies is vital for the safe treatment of inflammatory bowel disease, a disease affecting a young cohort of patients.The aim of this retrospective study was to assess the safety and
Autor:
Habib O. Ramadhani, Sendui Ole-Nguyaine, Humphrey J. Shao, Christopher W. Woods, John A. Crump, Andrew M. Moon, Leonard O. Uiso, John F. Shao, John Bartlett, Nathan M. Thielman, Rehema A. Kiwera
Publikováno v:
AIDS research and human retroviruses. 25(12)
Fixed dose combination abacavir/lamivudine/zidovudine (ABC/3TC/ZDV) among HIV-1 and tuberculosis (TB)-coinfected patients was evaluated and outcomes between early vs. delayed initiation were compared. In a randomized, pilot study conducted in the Kil
Publikováno v:
Expert review of anti-infective therapy. 7(7)
An ideal antibiotic regimen for Helicobacter pylori should achieve eradication rates of approximately 90%. Current 7-day triple therapy is successful in about two-thirds of patients. A novel treatment is required to achieve higher eradication with mi